A Study on Health Seeking Behaviors of Patients of Post-Kala-Azar Dermal Leishmaniasis.

Post-Kala-Azar Dermal Leishmaniasis (PKDL) remains a major public health threat in Bangladesh. A cross-sectional study was carried out in Surya Kanta Kala azar Research Centre (SKKRC), Mymensingh, from January 2012 to July 2013 to evaluate the health seeking behaviour and the length of delay of PKDL management. The consecutive 200 diagnosed PKDL cases that got treatment in SKKRC hospital were subjected to evaluation. Most (98%) of the patients were not aware and had no knowledge about PKDL, though 87.5% had a history of history of Kala-azar treatment. Many patients reported first to village doctor (15.5%), the pharmacy shop (10%), or traditional health provider (7.5%) upon recognition of symptom. The time between the initial symptom recognition and first medical consultation (patient delay) ranged from 10 days to 4745 days (13 years) with a median of 373 days (mean: 696; IQR: 138 to 900 days). The time between first medical consultations to definite treatment (system delay) ranged from 0 days to 1971 days (5.4 years), with a median delay of 14 days (mean: 46.48; IQR: 7 to 44 days) that was reported in this study. Age, education, occupation, and residential status had significant association with patient delay (P < 0.05). Educational status, occupation, number of treatment providers, and first health care provider had a significant association with system delay (P < 0.05). Success in PKDL diagnosis and treatment requires specific behavior from patients and health care providers which facilitate those practices.

A comparative study on effect of lamivudine in wild and precore mutant variety of chronic hepatitis B virus infected patients.

The aim of this study is to evaluate the effectiveness of lamivudine treatment in both precore mutant and wild type of chronic hepatitis B (CHB) patients. The study was done on sixty CHB patients of both sexes seeking treatment in the Outpatient Department and admitted patients of Mymensingh Medical College Hospital. The patients were divided into two groups. Group A included chronic hepatitis B patients with raised ALT (> 80 u/l ) with HBeAg positivity, and group B included precore mutant variety of CHB patients with raised ALT (> 80 u/l) with HBeAg negativity. In Group-A, after 1 year of completion of lamivudine therapy there was 86.67% normalization of ALT, 23.33% HBeAg loss, 16.67% anti-HBeAg development and 73.33% HBV DNA loss. In Group-B, there was 76.67% normalization of ALT and 73.33% HBV DNA loss after 1 year of completion of therapy. In the present study, it was observed that lamivudine is equally effective in both wild and precore mutant variety of CHB patients. This was reflected by normalization of ALT and loss of HBV DNA. This study also shows the reappearance of HBV DNA during the later half of Lamivudine therapy which is due to YMDD mutation.

Budd-Chiari syndrome.

A 30 years old, non-alcoholic farmer from Trishal, Mymensingh was admitted in Mymensingh Medical College Hospital on 7 February, 2004 with the complaints of gradual swelling of abdomen, both legs and upper abdominal pain for 3 months. For the last 6 years, he was treated as a case of chronic liver disease (CLD) with spironolactone and frusemide. He was non-icteric, mildly anaemic with mild oedema, clubbing, gynaecomastia and engorged vein over anterior abdominal wall, flanks and back. Direction of venous flow was from below upward. There were mild hepatosplenomegaly, ascites and bilateral testicular atrophy. He was diagnosed as a case of Budd-Chiari Syndrome (BCS) on the basis of physical examination and it was confirmed by the findings of ultrasonography, liver scan and doppler study. The patient was managed by medical therapy alone.